STOCK TITAN
  1. Home
  2. News
  3. ZOM

Zomedica Corp - ZOM STOCK NEWS

Welcome to our dedicated news page for Zomedica (Ticker: ZOM), a resource for investors and traders seeking the latest updates and insights on Zomedica.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Zomedica's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Zomedica's position in the market.

News
Senstar Technologies Corporation Reports Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
Senstar Technologies announced its financial results for the fourth quarter and full year of 2023. The company will host a conference call to discuss its operational and financial highlights on April 1st, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.88%
Tags
earnings
-
News
Zomedica to Present at the Noble Capital Markets Virtual Healthcare Conference on April 17, 2024
Rhea-AI Summary
Zomedica Corp. announced CEO Larry Heaton will present at Noble Capital Markets' Emerging Growth Virtual Healthcare Equity Conference. The presentation will include a Q&A session and 1x1 meetings with the management team. The event will be webcast live and available for 90 days on the company's website and Channelchek.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.62%
Tags
conferences
-
News
Zomedica Reports Record Revenue of $7.3 Million for the Fourth Quarter and $25.2 Million for the Full Year 2023, Reflecting 33% Annual Growth; 69% Gross Margin and $100.5 Million in Liquidity
Rhea-AI Summary
Zomedica Corp. (ZOM) reported strong financial results for Q4 and full year 2023, with revenue growth of 33% to $25.2 million driven by increases in Therapeutic Devices and Diagnostics segments. The company achieved record revenue in Q4, with 19% growth to $7.3 million. Zomedica made strategic acquisitions, launched new products, and expanded manufacturing capabilities in 2023. The company's cash position was robust at $100.5 million. However, Zomedica reported a net loss of $34.5 million for 2023, with increased operating expenses and research costs. Adjusted Non-GAAP EBITDA loss was $12.8 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Zomedica to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Monday, April 1, 2024, at 4:30 p.m. ET
Rhea-AI Summary
Zomedica Corp. (ZOM) will host a conference call to discuss its Q4 and Full Year 2023 financial results on April 1st, 2024. The call will cover operational and financial highlights for the period ended December 31, 2023, followed by a Q&A session.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.91%
Tags
conferences earnings
-
News
Zomedica Announces Publication of Research Concluding TRUFORMA(R) Platform is More Accurate Diagnostic Test for Feline Hyperthyroidism than Chemiluminescent Immunoassay (CLIA) Platform
Rhea-AI Summary
Zomedica Corp. (ZOM) announces a peer-reviewed research study comparing its TRUFORMA diagnostic platform for feline hyperthyroidism to CLIA platforms, showing improved accuracy. The study suggests TRUFORMA's BAW technology provides more precise results, aiding in early diagnosis. Zomedica collaborates with researchers to enhance animal healthcare, focusing on in-clinic diagnostics for various conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.6%
Tags
none
-
News
Zomedica Provides NYSE American Listing Update
Rhea-AI Summary
Zomedica Corp. is in dialogue with NYSE American to regain compliance with listing standards after receiving a notice in 2023. The company held a Special Meeting of Shareholders but failed to effect a share consolidation action. CEO Larry Heaton is optimistic about the future despite the risk of delisting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.6%
Tags
none
News
Zomedica Announces Sponsorship of Educational Presentations at Fetch dvm360 Veterinary Conferences
Rhea-AI Summary
Zomedica Corp. announces veterinary education programs at Fetch dvm360 Veterinary Conference, highlighting innovative technologies for animal healthcare professionals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.13%
Tags
none
-
News
Zomedica Announces Publication of Case Series Highlighting Success with PulseVet(R) Shock Wave Therapy for Difficult to Treat Fibrotic Myopathy in Working Dogs
Rhea-AI Summary
Zomedica Corp. announced the successful use of PulseVet shock wave therapy to treat fibrotic myopathy in working dogs. The therapy enabled dogs to continue working for an average of 32 months post-diagnosis. The study was published in Frontiers in Veterinary Science and conducted by experts at Schwarzman Animal Medical Center. PulseVet's therapy has shown efficacy in various conditions in canine and equine patients. The company aims to expand its market opportunities by exploring new indications for the therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.76%
Tags
none
-
News
Zomedica to Present at the Sidoti Small Cap Conference March 14, 2024
Rhea-AI Summary
Zomedica Corp. to present at Sidoti Small Cap Conference on March 14, 2024. Larry Heaton, CEO, to host one-on-one meetings with investors. Presentation to focus on point-of-care diagnostics and therapeutic products for animals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.16%
Tags
conferences
News
Zomedica Announces Sponsorship of Educational Presentations at Major Veterinary Health Conferences
Rhea-AI Summary
Zomedica Corp. continues its veterinary education mission through presentations at VMX and WVC meetings. The company aims to expand its reach and educate veterinarians about its diagnostic and therapeutic products for equine and companion animals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.79%
Tags
none
Stock ZOM logo
Zomedica Corp

Nasdaq:ZOM

ZOM Rankings

#4063 Ranked by Market Cap
#3990 Ranked by Stock Gains
N/A Ranked by Dividends

ZOM Stock Data

132.29M
963.34M
1.59%
8.89%
6.53%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Ann Arbor

About ZOM

zomedica (nyse american:zom) (tsx-v:zom) is a veterinary diagnostic and pharmaceutical and company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. zomedica’s product portfolio will include novel diagnostics and innovative therapeutics that emphasize patient health and practice health. with a team that includes clinical veterinary professionals, it is zomedica’s mission to give veterinarians the opportunity to lower costs, increase productivity, and grow revenue while better serving the animals in their care.